PDZ结合激酶:肺动脉高压血管重塑的新型调节因子
该研究通过转录组分析在多种肺动脉高压动物模型及人类PAH肺组织中鉴定出PBK(PDZ结合激酶)表达上调,PBK通过结合PRC1并促进胞质分裂驱动肺动脉平滑肌细胞增殖,药物抑制或基因敲除PBK可逆转或预防实验性PH。
要点
- PBK在多种PH模型及人类PAH的肺动脉中膜中表达上调,与平滑肌细胞标志物共定位。
- 药物抑制PBK在大小鼠模型中有效逆转PH,CRISPR/Cas9敲除PBK可预防PH发生。
- PBK通过结合PRC1并增加其磷酸化促进肺动脉平滑肌细胞胞质分裂和增殖。
核心结论
- PBK是PAH新靶点,在增殖的肺动脉平滑肌细胞中上调,通过改变胞质分裂和细胞周期动力学促进增殖,进而导致中膜增厚、纤维化、肺血管阻力增加、右心室收缩压升高、右心室重塑和PH。
研究设计与样本
- 研究分析与实验设计:Microarray、RNA测序、qPCR、Western blotting和免疫染色分析多种小鼠和大鼠PH模型及人类PAH的肺和分离肺动脉;PH评估采用数字超声、血流动力学测量和形态计量学。
主要发现
- Microarray分析高血压大鼠肺动脉转录组发现PBK在多种模型和物种(包括人类)中上调。
- PBK在肺动脉中膜层强烈上调,与平滑肌细胞标志物重叠。
- 功能获得实验显示活性PBK增加肺动脉平滑肌细胞增殖,而沉默PBK、显性负性PBK和PBK药理抑制剂均减少增殖。
- PBK药理抑制剂在大小鼠PH逆转策略中有效。
- CRISPR/Cas9敲除大鼠PBK可预防PH发生。
临床怎么用
- 临床转化意义:PBK药理抑制剂在大小鼠模型中有效逆转PH,提示PBK可能成为PAH治疗新靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary arterial hypertension (PAH) is high blood pressure in the lungs that originates from structural changes in small resistance arteries. A defining feature of PAH is the inappropriate remodeling of pulmonary arteries (PA) leading to right ventricle failure and death. Although treatment of PAH has improved, the long-term prognosis for patients remains poor, and more effective targets are needed. METHODS: Gene expression was analyzed by microarray, RNA sequencing, quantitative polymerase chain reaction, Western blotting, and immunostaining of lung and isolated PA in multiple mouse and rat models of pulmonary hypertension (PH) and human PAH. PH was assessed by digital ultrasound, hemodynamic measurements, and morphometry. RESULTS: Microarray analysis of the transcriptome of hypertensive rat PA identified a novel candidate, PBK (PDZ-binding kinase), that was upregulated in multiple models and species including humans. PBK is a serine/threonine kinase with important roles in cell proliferation that is minimally expressed in normal tissues but significantly increased in highly proliferative tissues. PBK was robustly upregulated in the medial layer of PA, where it overlaps with markers of smooth muscle cells. Gain-of-function approaches show that active forms of PBK increase PA smooth muscle cell proliferation, whereas silencing PBK, dominant negative PBK, and pharmacological inhibitors of PBK all reduce proliferation. Pharmacological inhibitors of PBK were effective in PH reversal strategies in both mouse and rat models, providing translational significance. In a complementary genetic approach, PBK was knocked out in rats using CRISPR/Cas9 editing, and loss of PBK prevented the development of PH. We found that PBK bound to PRC1 (protein regulator of cytokinesis 1) in PA smooth muscle cells and that multiple genes involved in cytokinesis were upregulated in experimental models of PH and human PAH. Active PBK increased PRC1 phosphorylation and supported cytokinesis in PA smooth muscle cells, whereas silencing or dominant negative PBK reduced cytokinesis and the number of cells in the G2/M phase of the cell cycle. CONCLUSIONS: PBK is a newly described target for PAH that is upregulated in proliferating PA smooth muscle cells, where it contributes to proliferation through changes in cytokinesis and cell cycle dynamics to promote medial thickening, fibrosis, increased PA resistance, elevated right ventricular systolic pressure, right ventricular remodeling, and PH.
引用
- Bordan Z, Batori RK, Haigh S, et al. PDZ-Binding Kinase, a Novel Regulator of Vascular Remodeling in Pulmonary Arterial Hypertension. Circulation. 2024. PMID: 38682326. doi:10.1161/CIRCULATIONAHA.123.067095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。